Takeda Raises Profit Forecast After 'Pandemic-Resistant' Q1
Aided By Chronic Portfolio
Japan’s largest pharma company says it has seen no impact on its financial results so far from the coronavirus pandemic, with continuing growth for mainstay drugs, and raises its profit forecasts for the fiscal year on favorable one-off factors.
You may also be interested in...
In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.